why choose us

Clinical Trials Search

Showing 19,140 of 132,963 result(s)
HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

Status: Completed

Condition: Unresectable Hepatocellular Carcinoma

Interventions: CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubic

Date: 2022-10-12

Blood Flow Reserve: Effects After Training With Heavy Inspiratory Exercises

Status: Completed

Condition: Coronary Artery Disease

Interventions: Participants will use the POWERbreathe KHP2 inspiratory muscle training device.
All participants will be assigned to perform 30 inspiratory maneu

Date: 2022-10-12

Virtual Reality in Pediatric Dentistry

Status: Completed

Condition: Behavior, Child

Interventions: The VR system will be worn for approximately 5-10 minutes during dental sealant application

Date: 2022-10-12

Prolonged Nightly Fasting in Fibromyalgia

Status: Completed

Condition: Fibromyalgia

Interventions: Participants will engage in 14+ hours a night of fasting and no calorie containing food or beverages for 8 weeks.
Participants will be allotted o

Date: 2022-10-12

TArgeting Type 1 Diabetes Using POLyamines (TADPOL)

Status: Completed

Condition: Type 1 Diabetes

Interventions: DFMO orally twice a day

Date: 2022-10-12

Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis

Status: Completed

Condition: Surgery

Interventions: 1 gram IV (intravenous) tranexamic acid administered in the operating room just prior to starting the case (10 minutes), at time that routine preopera

Date: 2022-10-12

Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors

Status: NOT_YET_RECRUITING

Condition: Advanced Solid Tumor

Interventions: Repeated 4-week intravenous infusion cycles of STI-6129 will be given.
(one infusion every four weeks).

Date: 2022-10-12

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

Status: Completed

Condition: Merkel Cell Carcinoma

Interventions: Pembrolizumab 400mg IV

Date: 2022-10-12

Phase 1 Seattle Dietary Biomarkers Development Center

Status: COMPLETED

Condition: Healthy Adults

Interventions: Crossover feeding study of three, 7-day feeding periods with plant and;or animal proteins (beef, pinto beans, and half beef;half pinto beans

Date: 2022-10-12

Self-Assembling Matrix Forming Gel to Prevent Stricture Formation

Status: COMPLETED

Condition: Esophageal Stricture

Interventions: Purastat is a fully synthetic matrix scaffold that can be applied through an endoscopic catheter.
Purastat is FDA approved and commercially avail

Date: 2022-10-12